MS pill drug firm blamed for ‘evidence failure’
Health campaigners have expressed disappointment after the medicines watchdog rejected the first pill to treat multiple sclerosis.
The MS Society urged the National Institute for Health and Clinical Excellence (Nice) and drug firm Novartis to work together so Gilenya (also called fingolimod) can be re-appraised.
In draft guidance which is subject to consultation, Nice rejected the drug because of “uncertainties” over its effectiveness, a lack of appropriate data and concerns over cost-effectiveness.
Advertisement
Hide Ad